Increased plasma xanthine oxidase activity is related to nuclear factor kappa beta activation and inflammatory markers in familial combined hyperlipidemia

Background and aimsXanthine oxidase (XO) has been described as one of the major enzymes producing free radicals in blood. Oxidative stress and inflammatory processes have been implicated in the pathogenesis of endothelial dysfunction and the progression of atherosclerosis but until now, there is little data about the influence of vascular prooxidant systems and inflammation in familial combined hyperlipidemia (FCH). Our goal was to evaluate whether XO activity was altered in FCH and if it was related to the inflammatory process represented by NFkB, IL-6 and hsCRP, and assessing the correlation between XO activity and insulin resistance (IR).Method and results40 Non-related subjects with FCH and 30 control subjects were included, all of them non-diabetic, normotensive and non-smokers. We measured lipid profile, glucose, insulin, uric acid, XO activity, malondialdehyde (MDA), IL-6 and hsCRP in plasma and NFkB activity in circulating mononuclear cells. Patients with FCH showed significantly higher levels of uric acid, XO activity, MDA, NFkB activity, IL-6 and hsCRP than controls. XO activity was independently related to NFkB activity with an odds ratio of 4.082; to IL-6 with an odds ratio of 4.191; and to IR with an odds ratio of 3.830. Furthermore, mean NFkB activity, IL-6 levels, and IR were highest in the highest percentile of XO activity.ConclusionsSubjects with FCH showed increased XO and NFkB activities and low grade inflammatory markers related to atherosclerosis. XO activity was correlated with higher inflammatory activity and IR. These data could explain, in part, the high cardiovascular disease risk present in these patients.     

小剂量氟伐他汀联合非诺贝特治疗老年混合型高脂血症的临床研究

目的观察小剂量氟伐他汀联合非诺贝特治疗老年混合型高脂血症的疗效及安全性。方法将入选的70例老年混合型高脂血症患者，随机分为氟伐他汀单药治疗组（12=35，20mg／d），氟伐他汀（20mg／d）、非诺贝特（200mg，隔日1次）联合治疗组（12=35），疗程均为12周。结果联合治疗组血脂参数变化最显著，降低低密度脂蛋白胆固醇、三酰甘油和升高高密度脂蛋白胆固醇的能力明显优于单药组（P〈0．01或P〈0．05），且未发现明显不良反应。结论小荆量氟伐他汀与非诺贝特联合治疗可以更有效地改善老年混合型高脂血症患者的血脂异常，具有良好的安全性和耐受性。     

Regulation of endothelial cell adhesion molecule expression in an experimental model of cerebral malaria

OBJECTIVE: Plasmodium falciparum malaria in humans and animal models of this disease have revealed changes in the infected host that are consistent with a systemic inflammatory response. Although it has been proposed that endothelial cell adhesion molecules (CAM) contribute to the adhesive interactions of Plasmodium-infected erythrocytes and immune cells with vascular endothelial cells, ECAM expression has not been systematically studied in Plasmodium-infected animals. METHODS: In this study, the dual radiolabeled monoclonal antibody method was used to quantify the expression of different ECAMs (ICAM-1, VCAM-1, P-selectin, E-selectin) in different regional vascular beds of Plasmodium berghei ANKA-inffected mice (PbA), a well-recognized model of human cerebral malaria. The roles of T lymphocytes and certain cytokines (TNF-alpha, IL-12, IFN-gamma) in mediating the infection-induced expression of ICAM-1 and P-selectin were assessed by using relevant mutant mice. RESULTS: Wild-type (WT) mice exhibited highly significant increases in the expression of ICAM-1, VCAM-1, and P-selectin (but not E-selectin) in all vascular beds on the 6th day of PbA infection. The PbA-induced upregulation of ICAM-1 was significantly blunted in mice that were either deficient in IFN-alpha, IL-12 (but not TNF1b) or T lymphocytes (Rag-1 deficiency); however, these responses were tissue specific. CONCLUSIONS: These findings indicate that vascular endothelial cells in most regional circulations assume an inflammatory phenotype and that cytokines and immune cells mediate this response in a tissue-specific manner.     

A novel mutation of the apolipoprotein A-I gene in a family with familial combined hyperlipidemia

We report a large family in which four members showed a plasma lipid profile consistent with the clinical diagnosis of familial combined hyperlipidemia (FCHL). One of these patients was found to have markedly reduced HDL cholesterol (HDL-C) (0.72 mmol/l) and Apo A-I (72 mg/dl) levels, a condition suggestive of the presence of a mutation in one of the HDL-related genes. The analysis of APOA1 gene revealed that this patient was heterozygous for a cytosine insertion in exon 3 (c.49–50 ins C), resulting in a frame-shift and premature stop codon at position 26 of pro-Apo A-I (Q17PFsX10). This novel mutation, which prevents the synthesis of Apo A-I, was also found in four family members, including three siblings and the daughter of the proband. Carriers of Apo A-I mutation had significantly lower HDL-C and Apo A-I than non-carriers family members (0.77 ± 0.15 mmol/l vs. 1.15 ± 0.20 mmol/l, P < 0.005; 71.4 ± 9.1 mg/dl vs. 134.0 ± 14.7 mg/dl, P < 0.005, respectively). Two of the APOA1 mutation carriers, who were also heavy smokers, had fibrous plaques in the carotid arteries causing mild stenosis (20%). The intimal-media thickness in the two other adult carriers was within the normal range. The other non-carriers family members with FCHL had either overt vascular disease or carotid atherosclerosis at ultrasound examination. This observation suggests that the low HDL-C/low Apo A-I phenotype may result from a genetic defect directly affecting HDL metabolism, even in the context of a dyslipidemia which, like FCHL, is associated with low plasma HDL-C.     

Serum concentrations of E-selectin, P-selectin, ICAM-1 and interleukin 6 in acute leukaemia patients with chemotherapy-induced leucopenia and bacterial infections

Summary. Serum concentrations of E-selectin (CD62E), P-selectin (CD62P), ICAM-1 (CD54) and interleukin 6 were investigated in acute leukaemia patients with chemotherapy-induced leucopenia and complicating bacterial infections. Serum concentrations of both E-selectin and P-selectin were decreased in the leucopenic patients without infections when compared with levels before chemotherapy; and serum concentrations of both E-selectin and P-selectin showed a further decrease during complicating bacterial infections. In contrast to the leukaemia patients, previously healthy individuals with meningococcal disease showed markedly elevated serum concentrations of E-selectin and normal levels of P-selectin during infection. Serum concentrations of ICAM-1 and interleukin 6 increased during bacterial infections in the acute leukaemia patients with chemotherapy-induced leucopenia. The alterations in serum concentrations of soluble adhesion molecules and interleukin 6 reversed when clinical signs of bacterial infections resolved during antibiotic therapy. Our results demonstrate that acute leukaemia patients with chemotherapy-induced cytopenia show altered levels of both soluble adhesion molecules and interleukin 6 during complicating bacterial infections.     

Insulin resistance and oxidative stress in familial combined hyperlipidemia

Oxidative stress is associated with atherosclerosis. Familial combined hyperlipidemia (FCH) is considered as a human model of primary dyslipidemia and atherosclerosis frequently associated with insulin resistance (IR), but there are few data on its possible relation to oxidative stress. The objective of this study was to evaluate oxidative stress status using different markers in subjects with FCH assessing its possible correlation with anthropometric parameters and IR. This was a cross-sectional study. A cohort of 40 FCH patients (20 with IR (HOMA ≥ 3.2) and 20 without IR (HOMA < 3.2)), and 20 healthy volunteers were included, all of them non-diabetic, normotensive and non-smokers. We measured lipid profile, glucose and insulin levels in plasma, HOMA, and representative indicators of oxidative stress such as 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG), reduced glutathione (GSH), oxidized glutathione (GSSG) and GSSG/GSH ratio in mononuclear cells. All parameters were determined at basal conditions with standard methodology in the three groups. All FCH subjects showed an increased status of oxidative stress compared to the control group. When the impact of IR was investigated, significant differences between groups were observed in terms of increased levels of 8-oxo-dG, GSSG and GSSG/GSH ratio in FCH subjects with IR indicating higher levels of oxidative stress in these patients. Correlation studies showed that 8-oxo-dG and GSSG/GSH ratio are independently related to IR with odds ratio of 3.5 and 7.4, respectively. We conclude that FCH is related to oxidative stress, especially in the presence of IR.     

血浆apoB100水平升高不宜作为家族性混合型高脂血症与家族性高胆固醇血症鉴别诊断的指标

目的 探讨家族性混合型高脂血症与家族性高胆固醇血症血浆载脂蛋白A1（apoA1)、载脂蛋白B100（apoB100)水平的异同。方法 病例－对照／家系设计,家族性混合型高脂血症家系15个（93人）;家族性高胆固醇血症家系11个（94人）;对照家系12个（67人）。比较家系间及家系内受累组与未受累组血浆apoA1与apoB100水平。结果 两种高脂血症家系间及两种家系内受累组间血浆apoA1与apoB100水平未见统计学显著性差异;与对照家系相比,两种高脂血症家系血浆apoB100水平均显著升高（P＜0．01）,同时,家系内受累组血浆apoB100水平显著高于未受累组（P＜0．01）。结论 两种高脂血症家系受累组血浆apoB100水平均显著升高,故血浆apoB100水平升高不宜作为家族性混合型高脂血症与家族性高胆固醇血症鉴别诊断的指标。     

Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia

Objective

Controversial findings exist regarding potential influence of statin therapy on diabetic incidence. Aim of this study was to investigate the role of long duration statin treatment on diabetes mellitus (DM) incidence of Heterozygous Familial Hypercholesterolemia (hFH) and Familial Combined Hyperlipidemia (FCH) patients.

Methods

Study population consisted of 212 hFH and 147 FCH patients that visited Lipid Outpatient Department (mean follow up of 11 and 10 years respectively). Several clinical data such as history of DM, cardiovascular disease, thyroid function, metabolic syndrome, glucose levels, lipid profile and lifestyle data were obtained. In order to compare the effects of different doses of different types of statins, a “statin treatment intensity product” was used.

Results

14% of FCH and only 1% of hFH patients developed DM during follow up. Although univariate analysis showed a statistical trend (p = 0.06) in the association between new onset DM and statin treatment intensity (STI) in the FCH subgroup of patients with normal baseline glucose levels, this was no longer significant after adjusting for several confounders. Furthermore, the type of statins used did not seem to play a role in the development of DM either in hFH or FCH patients.

Conclusion

Long duration of high STI does not seem to be associated with diabetic risk in hFH patients. High STI used in the FCH population is not associated with increased risk of new onset DM compared to low STI. Further studies are required in order to clarify the potential diabetogenic effects of statins in these high risk populations.     

Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin

BACKGROUND AND AIM: Elevation of plasma cholesterol and/or triglycerides, and the prevalence of small dense low density lipoproteins (LDL) particles remarkably increase the risk in patients with familial combined hyperlipidemia (FCHL). There are, at present, inconsistent data on the effects of different treatments on size and density of LDL particles in FCHL patients. METHODS AND RESULTS: A multicenter, randomized, double-blind, double-dummy, parallel group study was designed to evaluate the effect of 3 months' treatment with atorvastatin (10mg/day) or pravastatin (20mg/day) on the lipid/lipoprotein profile and LDL size in a total of 86 FCHL patients. Both statins significantly lowered plasma total and LDL cholesterol, with a significantly higher hypocholesterolemic effect observed with atorvastatin (-26.8+/-11.1% and -35.9+/-11.1%, respectively) compared to pravastatin (-17.6+/-11.1% and -24.5+/-10.2%). The percent decrease in plasma triglycerides was highly variable, but more pronounced with atorvastatin (-19.8+/-29.2%) than with pravastatin (-5.3+/-48.6%). Opposite changes in LDL size were seen with the 2 treatments, with increased mean LDL particle diameter with atorvastatin, and decreased diameter with pravastatin, and significant between treatment difference in terms of percent modification vs baseline (+0.5+/-1.6% with atorvastatin vs -0.3+/-1.8% with pravastatin). CONCLUSIONS: The present results support the evidence indicative of a greater hypocholesterolemic effect of atorvastatin compared to pravastatin, and in addition show a raising effect of atorvastatin on the size of LDL particles in FCHL patients.     

Pulse wave velocity in familial combined hyperlipidemia

BACKGROUND: In the present cross-sectional study we investigated whether familial combined hyperlipidemia (FCH) is associated with an increased arterial wall stiffness, and whether measures of arterial wall stiffness in FCH family members could contribute to cardiovascular risk stratification. METHODS: Ninety-eight subjects with FCH and 230 unaffected relatives filled out a questionnaire about their smoking habits, medical history, and medication use. Fasting venous blood was drawn after discontinuation of any lipid-lowering medication. Pulse wave velocity (PWV) and augmentation index (AIx) were determined by applanation tonometry as surrogate markers of arterial stiffness. RESULTS: Patients with FCH had a significantly increased PWV compared to their unaffected relatives (9.07 +/- 2.75 v 8.28 +/- 2.62 m/sec, P = .005), whereas AIx was not increased (21.6 +/- 12.7 v 15.6 +/- 14.1, P = .96). Age- and gender-adjusted PWV was an equally good predictor of the presence of cardiovascular disease (CVD) in FCH family members as the most predictive combination of age- and gender-adjusted clinical and biochemical risk factors, including total cholesterol, HDL-cholesterol, and systolic blood pressure (area under the receiver operating curve (ROC) [AUC] 0.83 [0.76-0.90] v AUC 0.84 [0.78-0.91], P = .83). Addition of PWV to the multivariable prognostic model, including these age- and gender-adjusted traditional risk factors, did not increase the predictive ability for CVD (AUC 0.84 [0.79-0.89]). CONCLUSIONS: Patients with FCH are characterized by an increased arterial stiffness. The PWV predicts the presence of CVD equally well as any combination of clinical and traditional biochemical risk factors, but PWV has no additional value in addition to traditional risk factor screening in FCH families.     

溃疡性结肠炎患者外周血中性粒细胞凋亡与粘附分子水平的关系及意义

目的　探讨溃疡性结肠炎 (U C)患者外周血中性粒细胞 (PMN)凋亡机制。方法　采用流式细胞术检测 32例 UC患者外周血 PMN凋亡 ,EL ISA法检测 P-选择素 (P- sel)和细胞间粘附分子 - 1(ICAM- 1)的水平。结果　活动期 UC患者 PMN凋亡率明显低于对照组和缓解期 UC患者 (P<0 .0 1)。不同病情活动期 U C患者 PMN凋亡有显著性差异 (P<0 .0 1)。活动期 UC患者外周血中 P- sel和 ICAM- 1水平均高于对照组和缓解期 U C患者(P<0 .0 1或 (P<0 .0 5 ) ,且与 PMN凋亡呈负相关 (r值分别为 - 0 .72 38和 - 0 .5 2 13,P均 <0 .0 1) ,与病情呈正相关。结论　各种免疫细胞粘附分子表达上调可能是导致 UC患者 PMN凋亡延迟的重要机制     

缺血性卒中患者血清可溶性E选择素和P选择素水平的变化

目的探讨不同时间、不同病情的缺血性卒中患者血清中可溶性E选择素、P选择素水平的变化及其临床意义。方法缺血性卒中患者54例,根据神经功能缺损程度,将患者分为轻型(26例)、中型(16例)和重型(12例)；另外选取30名体格检查正常者为对照组。采用酶联免疫吸附法(ELISA)测定不同时期、不同程度患者和对照组对象血清中的可溶性E选择素、P选择素的水平。结果①缺血性卒中组患者在发病后12、24、72h和7d血清E选择素分别为(53±8)、(60±9)、(70±9)和(51±8)μg／L。P选择素水平分别为(18±4)、(25±6)、(30±6)和(21±4)μg／L。②轻型患者在发病后72h血清可溶性E选择素、P选择素分别为(61±9)和(23±5)μg／L；中型为(80±11)和(41±9)μg／L；重型为(84±12)和(49±10)μg／L。结论缺血性卒中患者急性期血清中的可溶性E选择素、P选择素水平升高,可以作为判断病情严重程度的血清学指标之一。     

替米沙坦联合阿托伐他汀对2型糖尿病合并冠心病患者的疗效观察

目的探究替米沙坦联合阿托伐他汀治疗2型糖尿病(T2DM)合并冠心病患者的效果,并观察其对血清可溶性P选择素(sP-selectin)、可溶性E选择素(sE-selectin)的影响。方法选取在我院就诊的114例老年T2DM合并冠心病患者作为研究对象。采用随机数字表法分组,分为观察组和对照组各57例,对照组予阿托伐他汀治疗,每次20mg,1次/d,并予胰岛素控制血糖等常规治疗。观察组在对照组治疗基础上加用替米沙坦,每次80 mg,1次/d,2组疗程均为2个月。对比2组患者治疗前后血脂、血清sP-selectin、sE-selectin变化情况以及治疗后不良事件发生率。结果2组患者治疗前血脂水平比较无显著差异(P>0.05),与治疗前比较,2组治疗后TG、TC、LDL-C水平明显降低,差异有统计学意义(P<0.01);与对照组比较,观察组治疗后TG、TC、LDL-C显著降低[(2.02±0.66)mmol/L vs(2.54±0.78)mmol/L,P=0.001;(4.65±0.58)mmol/L vs(5.21±0.65)mmol/L,P=0.000;(2.15±0.59)mmol/L vs(2.89±0.83)mmol/L,P=0.001]。2组患者治疗前血清sP-selectin、sE-selectin水平比较无统计学差异(P>0.05);与对照组比较,观察组治疗后血清sP-selectin、sE-selectin水平显著降低[(56.97±8.64)μg/Lvs(66.38±11.25)μg/L,P<0.01;(561.09±14.32)μg/Lvs(612.84±21.10)μg/L,P<0.01]。治疗期间2组不良反应发生率比较无显著差异(P>0.05)。结论替米沙坦联合阿托伐他汀应用于T2DM合并冠心病患者能降低血清sP-selectin和sE-selectin表达水平,降低患者的血脂,可改善心血管疾病预后。     

阿托伐他汀联合非诺贝特治疗老年混合型高脂血症临床疗效观察

目的 探讨中等剂量阿托伐他汀片剂和非诺贝特胶囊联合应用治疗混合性高脂血症的临床疗效及安全性.方法 混合性高脂血症患者226例,随机分为：阿托伐他汀组112例,阿托伐他汀（20 mg/d）治疗;联合治疗组114例,阿托伐他汀（20 mg/d）和非诺贝特胶囊（200 mg/d）共治疗3个月.观察治疗前、后各项血脂参数的变化、达标率及不良反应.结果 除阿托伐他汀组高密度脂蛋白胆固醇（HDL-C）水平与治疗前相比无明显改善[（0.99±0.27）mmol/L比（0.95±0.24）mmol/L,P＞0.05]外,两组患者各项血脂参数如血清总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）和甘油三酯（TG）水平与治疗前相比均有不同程度的改善[阿托伐他汀组：（4.22±0.46）mmol/L比（7.18±0.52）mmol/L,（2.76±0.34）mmol/L比（4.46±0.43）mmol/L,（3.05±0.44）mmol/L比（3.81±0.48）mmol/L;联合治疗组：（3.43±0.42）mmol/L比（7.15±0.50）mmol/L,（2.18±0.31）mmol/L比（4.44±0.42）mmol/L,（1.62±0.31）mmol/L比（3.85±0.51）mmol/L;P均＜0.05],但联合治疗组TG、TC、LDL-C降低的幅度和HDL-C升高幅度较大[（3.05±0.44）mmol/L比（1.62±0.31）mmol/L,（4.22±0.46）mmol/L比（3.43±0.42）mmol/L,（2.76±0.34）mmol/L比（2.18±0.31）mmol/L,（1.23±0.30）mmol/L比（0.99±0.27）mmol/L,P均＜0.05],达标率更高（69.6%比13.4%,83.3%比71.4%,80.7%比67.9%,49.1%比9.8%,P均＜0.05）,明显优于阿托伐他汀组,两组患者不良反应的发生率相比差异无统计学意义（P＞0.05）.结论 中等剂量阿托伐他汀（20 mg/d）和非诺贝特胶囊（200 mg/d）联合应用对混合性高脂血症患者具有良好的安全性和有效性,值得临床推广应用.     

细胞间黏附分子-1和P-选择素的表达与非小细胞肺癌关系的研究

目的探讨细胞间黏附分子-1(ICAM-1)和P-选择素在肺癌转移机制中的作用。方法采用免疫组化SP法对52例原发性肺癌组织的ICAM-1及P-选择素的表达进行检测。结果(1)肺癌的ICAM-1和P-选择素阳性表达明显高于癌旁组织;(2)ICAM-1及P-选择素在腺癌组织中的阳性表达率显著高于鳞癌,两者在Ⅲ Ⅳ期患者的阳性表达明显高于Ⅰ Ⅱ期;(3)肺癌中有淋巴结转移的ICAM-1的阳性表达率显著高于无淋巴结转移,而P-选择素的表达与淋巴结转移无明显相关性。结论ICAM-1和P-选择素可能与肺癌的浸润转移有关。     

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

Given that combination therapy with statin plus fibrate confers a risk of myopathy, it is worthwhile to determine whether statin or fibrate monotherapy is associated with greater clinical benefit in individuals with combined hyperlipidemia. In this randomized double-blind study, we compared the efficacy of simvastatin and fenofibrate on indexes of endothelial function (flow-mediated dilation (FMD) of the brachial artery) and inflammatory markers (plasma high-sensitivity C-reactive protein (CRP), interleukin-1β (IL-1β), soluble CD40, and soluble CD40 ligand (sCD40L) levels), as surrogate indicators of future coronary heart disease (CHD), in patients with combined hyperlipidemia. A total of 70 patients with plasma triglyceride levels between 200 and 500 mg/dl and total cholesterol levels of >200 mg/dl were randomly assigned to receive either simvastatin (20 mg/day) (n=35) or micronized fenofibrate (200 mg/day) (n=35) for 8 weeks. Treatment with simvastatin was associated with significantly greater reduction of total cholesterol and low-density lipoprotein cholesterol (LDL-C), while the decrease in triglycerides was significantly greater in patients receiving fenofibrate. Both fenofibrate and simvastatin markedly reduced plasma levels of high-sensitivity CRP, IL-1β, and sCD40L, and improved endothelium-dependent FMD without mutual differences. The changes in plasma inflammatory markers did not correlate with baseline clinical characteristics in both groups. However, the improvement in FMD with fenofibrate treatment correlated inversely with baseline high-density lipoprotein cholesterol (HDL-C) levels, whereas the improvement in FMD with simvastatin treatment was positively related to HDL-C levels. Accordingly, in the subgroup with a baseline HDL-C of ≤40 mg/dl, only fenofibrate significantly improved the endothelium-dependent FMD. On the other hand, in the subgroup with HDL-C >40 mg/dl, only treatment with simvastatin achieved significant improvement in FMD. The data here indicate that in patients with combined hyperlipidemia, both fenofibrate and simvastatin have comparative beneficial effects on various inflammatory markers and differential beneficial effects on endothelial function according to baseline HDL-C levels. These findings should be validated by additional prospective studies, in which patients are stratified by baseline HDL-C prior to randomization.     

复方苦豆子对肾性高血压复合高脂血症大鼠血浆内皮素和一氧化氮合成酶的影响

目的研究复方苦豆子(CK)对肾性高血压复合高脂血症大鼠血压、体质量、肝脏脂质、血浆内皮素(ET)、总一氧化氮合成酶(T-NOS)及结构型一氧化氮合成酶(cNOS)的影响。方法建立二肾一夹(2K1C)肾性高血压复合高脂血症大鼠模型。随机分为5组,模型组;CK高、中、低剂量组;阳性对照组;每组12只。每天灌胃脂肪乳的同时,给予不同的干预措施,连续8周。另取10只为假手术组。给药前及给药1、2、4、8周观察大鼠体质量变化;给药8周测大鼠尾动脉收缩压及心率;检测大鼠ET、T-NOS和cNOS;肝脏脂质(TC、TG)。结果用药2周后,模型组大鼠体质量呈下降趋势,状态较差;各给药组大鼠体质量与模型组比较有所升高,用药4周后升高明显(P<0.05),状态良好;给药8周后,中、高剂量与模型组相比血压明显下降、明显降低血浆ET、肝匀浆中的TC和TG含量、升高T-NOS和cNOS含量(P<0.01)。结论 CK可降低高血压复合高脂血症模型大鼠的血压,调节肝脏脂质,并推测其降压调脂作用机制与内皮系统的调节有关。